Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 21902-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#21902-1-AP, RRID:AB_10897159
- Product name
- TMED3 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated TMED3 antibody (Cat. #21902-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references TMEDs mediate versatile cargo transport in vesicle-dependent unconventional secretion.
Chromosomal 3q amplicon encodes essential regulators of secretory vesicles that drive secretory addiction in cancer.
Analysis and Validation of TMED3 correlates with poor prognosis and tumor immune infiltration of glioma.
Screening of the novel immune-suppressive biomarkers of TMED family and whether knockdown of TMED2/3/4/9 inhibits cell migration and invasion in breast cancer.
TMED3 exerts a protumor function in non-small cell lung cancer by enhancing the Wnt/β-catenin pathway via regulation of AKT.
TMED3 Promotes Proliferation and Migration in Breast Cancer Cells by Activating Wnt/β-Catenin Signaling.
Down-regulation of the islet-specific zinc transporter-8 (ZnT8) protects human insulinoma cells against inflammatory stress.
Zheng J, Wang H, Sun Y, Chang P, Deng X, Zhang L, Zhu L, Zhu K, Peng D, Deng H, Zhang M, Ge L
The Journal of cell biology 2026 Jan 5;225(1)
The Journal of cell biology 2026 Jan 5;225(1)
Chromosomal 3q amplicon encodes essential regulators of secretory vesicles that drive secretory addiction in cancer.
Tan X, Wang S, Xiao GY, Wu C, Liu X, Zhou B, Jiang Y, Duose DY, Xi Y, Wang J, Gupta K, Pataer A, Roth JA, Kim MP, Chen F, Creighton CJ, Russell WK, Kurie JM
The Journal of clinical investigation 2024 Apr 25;134(12)
The Journal of clinical investigation 2024 Apr 25;134(12)
Analysis and Validation of TMED3 correlates with poor prognosis and tumor immune infiltration of glioma.
Liao G, Zhang M, Wang C
Journal of cancer research and clinical oncology 2023 Jul;149(7):3485-3494
Journal of cancer research and clinical oncology 2023 Jul;149(7):3485-3494
Screening of the novel immune-suppressive biomarkers of TMED family and whether knockdown of TMED2/3/4/9 inhibits cell migration and invasion in breast cancer.
Fang Z, Song YX, Wo GQ, Zhou HL, Li L, Yang SY, Chen X, Zhang J, Tang JH
Annals of translational medicine 2022 Dec;10(23):1280
Annals of translational medicine 2022 Dec;10(23):1280
TMED3 exerts a protumor function in non-small cell lung cancer by enhancing the Wnt/β-catenin pathway via regulation of AKT.
Zhang D, Sun L, Zhang J
Toxicology and applied pharmacology 2021 Dec 15;433:115793
Toxicology and applied pharmacology 2021 Dec 15;433:115793
TMED3 Promotes Proliferation and Migration in Breast Cancer Cells by Activating Wnt/β-Catenin Signaling.
Zhang X, Luo Y, Li Q
OncoTargets and therapy 2020;13:5819-5830
OncoTargets and therapy 2020;13:5819-5830
Down-regulation of the islet-specific zinc transporter-8 (ZnT8) protects human insulinoma cells against inflammatory stress.
Merriman C, Fu D
The Journal of biological chemistry 2019 Nov 8;294(45):16992-17006
The Journal of biological chemistry 2019 Nov 8;294(45):16992-17006
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The TMED3 antibody from Proteintech is a rabbit polyclonal antibody to a fusion protein of human TMED3. This antibody recognizes human, mouse, rat antigen. The TMED3 antibody has been validated for the following applications: ELISA, WB analysis.
